About this Research Topic
Patient-specific pluripotent stem cells can be generated using induced pluripotent stem cells (iPSC) technology, making it a promising platform for drug discovery and cell therapy in metabolic diseases. Isogenic iPSC lines can be created using state-of-the-art gene-editing technologies to investigate the underlying mechanisms of metabolic disease development and progression. Additionally, stem cell-derived organoids that closely resemble naive tissues/organs provide an excellent tool for metabolic disease modeling, drug screening, and cell therapy. Meanwhile, patient-specific iPSCs and organoid biobanking will benefit precision medicine.
This Research Topic focuses on the applications of stem cells and organoids in metabolic disease modeling, drug discovery, and cell therapy, as well as the identification and investigation of tissue stem cell functions in metabolic tissues. We welcome Original Research articles, Review articles, and Perspectives on themes including, but not limited to:
- Identification of tissue stem cells in the liver, pancreas, etc.;
- Cellular heterogeneity of liver, adipose, and pancreas;
- Develop advanced and complexed liver, adipose, and pancreas organoids;
- Metabolic disease modeling using patient-derived iPSCs or organoids;
- Stem cell therapies for metabolic diseases;
- Drug discovery and precision medicine using stem cell and organoid model.
Keywords: stem cell, organoid, metabolism, precision medicine, disease modeling
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.